Idiopathic inflammatory myositis is associated with a high incidence of hypertension and diabetes mellitus

International Journal of Rheumatic Diseases

Volumn 13, Issue 2, 2010, Pages 132-137

  Limaye, Vidya S ^a,b   Lester, Sue ^c   Blumbergs, Peter ^c   Roberts Thomson, Peter J ^d  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c HANSON INSTITUTE   (Australia)

^d SA PATHOLOGY   (Australia)

Author keywords

Dermatomyositis; Inclusion body myositis; Inflammatory myositis; Polymyositis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISOLONE; ANTIINFLAMMATORY AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DERMATOMYOSITIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; IDIOPATHIC INFLAMMATORY MYOSITIS; INCIDENCE; INCLUSION BODY MYOSITIS; ISCHEMIC HEART DISEASE; MALE; MORBIDITY; MUSCLE BIOPSY; MYOSITIS; POLYMYOSITIS; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; ADOLESCENT; AUSTRALIA; COMORBIDITY; MIDDLE AGED; MYOSITIS, INCLUSION BODY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; COMORBIDITY; DERMATOMYOSITIS; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; MIDDLE AGED; MYOSITIS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS; RISK FACTORS; SOUTH AUSTRALIA; YOUNG ADULT;

EID: 77953796498     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2010.01470.x     Document Type: Article

References (22)

1. Hohlfeld R. Polymyositis and dermatomyositis. Structural and Molecular Basis of Skeletal Muscle Diseases 2002, 221-7. Karpati G. In, eds, pp, ISN Neuropath Press, Switzerland
2. Sultan SM, Ioannou Y, Moss K, Isenberg DA. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology 2002, 41(1):22-6.
3. Airo A, Kautiainen H, Hakala M. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006, 25:234-9.
4. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000, 16(4):505-11.
5. Roman MJ, Shanker BA, Davis A. Prevalence and correlates of accelerated atherosclerois in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-406.
6. Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis 2007, 192(2):376-83.
7. 2-56.
8. Yildrim Donmez F, Feldman F. Muscle compromise in diabetes. Acta Radiol 2008, 49(6):673-9.
9. Narayanaswamy AS, Akhtar M, Kumar N, Lazar AI. Polymyositis-a review and follow up study of 24 cases. J Assoc Physicians India 1993, 41(6):354-6.
10. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis. Observations in 40 patients. Brain 1989, 112(Pt 3):727-47.
11. Luther HP, Homuth V, Wallukat G. Alpha 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension 1997, 29(2):678-82.
12. Fu ML, Herlitz H, Schulze W. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000, 18(7):945-53.
13. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA, Sowers JR. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol 2008, 294(3):R673-80.
14. Stump CS, Henriksen EJ, Wei Y, Sowers JR. The metabolic syndrome: role of skeletal muscle metabolism. Ann Med 2006, 38(6):389-402.
15. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006, 5(5):331-7.
16. Lundberg IE, Forbess CJ. Mortality in idiopathic inflammatory myopatheis. Clin Exp Rheumatol 2008, 26(Suppl 51):S109-14.
17. Henriksson KG, Sandstedt P. Polymyositis -treatment and prognosis: a study of 107 patients. Acta Neurol Scand 1982, 65:280-300.
18. Bohan Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292(7):344-7.
19. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases. Curr Vasc Pharmacol 2010, (Epub ahead of print)
20. Gasparyan AY, Ugurlucan M. The emerging issue of cardiovascular involvement in familial Mediterranean fever. Arch Med Sci 2008, 4(4):465-7.
21. Turesson C, Jacobsson LT, Matteson EL. Cardiovascular co-morbidity in rheumatic diseases. Vasc Health Risk Manag 2008, 4(3):605-14.
22. Ng KP, Ramos F, Sultan SM, Isenberg DA. Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. Clin Rheumatol 2009, 28:947-53.